Medical isotope firm Shine Medical Technologies has appointed Harrie Buurlage as vice president (VP) of European operations.
Buurlage will oversee the company's activities on the continent, including the siting, construction, and operation of a medical isotope production facility to be located there, according to the company.
Buurlage previously served as chief operating officer and then managing director of the Nuclear Research and Consultancy Group (NRG) in the Netherlands, guiding NRG's nuclear installations, including the High Flux Reactor medical isotope production facility in Petten. Prior to his time at NRG, Buurlage was the global director of manufacturing for Covidien, now Curium Pharma, where he was responsible for radiopharmaceutical isotope manufacturing and distribution at facilities in the Netherlands, the U.K., and the U.S.